Biomarin Pharmaceutical Inc. (BMRN)
Here's Why You Should Invest in BioMarin (BMRN) Stock Now
Here, we are discussing some reasons why investing in BioMarin (BMRN) stock now may turn out to be a prudent move.
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why
BioMarin (BMRN) could produce exceptional returns because of its solid growth attributes.
Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance
BioMarin Pharmaceutical Inc. BMRN announced an update on its Roctavian business to focus commercial operations on three markets: the U.S., Germany and Italy.
BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View
BioMarin (BMRN) posts better-than-expected second quarter earnings. It also raises its revenue and earnings guidance for full-year 2024.
BioMarin: Q2 Revenue Soars 20%
Revenue for Q2 2024 totaled $712 million, a 20% year-over-year increase. Management raised full-year 2024 guidance, reflecting the company's optimistic outlook.
BioMarin Pharmaceutical Inc. (BMRN) Q2 2024 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q2 2024 Results Conference Call August 5, 2024 5:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Alexander Hardy - President and Chief Executive Officer Hank Fuchs - President, Worldwide Research & Development Brian Mueller - Executive Vice President, Chief Financial Officer Cristin Hubbard - Executive Vice President, Chief Commercial Officer Conference Call Participants Phil Nadeau - TD Cowen Salveen Richter - Goldman Sachs Ellie Merle - UBS Cory Kasimov - Evercore Jessica Fye - JPMorgan Paul Matteis - Stifel Joseph Schwartz - Leerink Partners Chris Raymond - Piper Sandler Gena Wang - Barclays Kostas Biliouris - BMO Capital Markets Mohit Bansal - Wells Fargo Olivia Brayer - Cantor Fitzgerald Luca Issi - RBC Capital Operator Good afternoon, and welcome to the BioMarin Pharmaceuticals Second Quarter 2024 Conference Call. Please note that this call is being recorded.
BioMarin (BMRN) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.54 per share a year ago.
Wall Street's Insights Into Key Metrics Ahead of BioMarin (BMRN) Q2 Earnings
Evaluate the expected performance of BioMarin (BMRN) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Why BioMarin (BMRN) is Poised to Beat Earnings Estimates Again
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q2 Release
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
